Table 1.
Characteristics of Participant from the 3 Clinical Trials.
| Polyp Prevention Study | ||||
|---|---|---|---|---|
| Antioxidants N (%) |
Calcium N (%) |
Aspirin/Folate N (%) |
Total N (%) |
|
| Entry characteristics | ||||
| N | 724 | 780 | 926 | 2430 |
| Age, mean years (SD) | 61.0 (8.3) | 60.6 (9.0) | 57.3 (9.7) | 59.5 (9.2) |
| Sex (male) | 574 (79.3) | 555 (71.2) | 580 (62.6) | 1709 (70.3) |
| Race (non-white) | 105 (14.6) | 118 (15.1) | 127 (13.7) | 350 (14.4) |
| Location of baseline adenomas | ||||
| Distal only | 383 (52.9) | 392 (50.3) | 491 (53.0) | 1266 (52.1) |
| Proximal only | 108 (14.9) | 141 (18.1) | 273 (29.5) | 522 (21.5) |
| Both sides | 233 (32.2) | 247 (31.7) | 162 (17.5) | 642 (26.4) |
| Subjects with ≥2 adenomas, distal only | 128 (17.7) | 128 (16.4) | 97 (10.5) | 353 (14.5) |
| Subjects with ≥2 adenomas, proximal only | 44 (6.1) | 61 (7.8) | 70 (7.6) | 175 (7.2) |
| Location of baseline advanced adenomas | ||||
| Distal only | 306 (42.3) | 220 (28.2) | 193 (20.8) | 719 (29.6) |
| Proximal only | 56 (7.7) | 44 (5.6) | 55 (5.9) | 155 (6.4) |
| Both sides | 45 (6.2) | 34 (4.4) | 15 (1.6) | 94 (3.9) |
| Follow-up events | ||||
| Mean follow-up, mean months (SD) | 36.6 (2.7) | 36.7 (3.5) | 37.6 (4.1) | 37.0 (3.6) |
| Subjects with at least one adenoma | 268 (37.0) | 264 (33.8) | 355 (38.3) | 877 (36.5) |
| Distal only | 105 (14.5) | 77 (9.9) | 140 (15.1) | 322 (13.3) |
| Proximal only | 110 (15.2) | 131 (16.8) | 151 (16.3) | 392 (16.1) |
| Both sides | 53 (7.3) | 56 (7.2) | 64 (6.9) | 173 (7.1) |
| Subjects with advanced adenomas (%) | 64 (8.8) | 64 (8.2) | 82 (8.5) | 210 (8.5) |
| Distal only | 30 (4.1) | 20 (2.6) | 34 (3.7) | 84 (3.5) |
| Proximal only | 30 (4.1) | 41 (5.3) | 45 (4.9) | 116 (4.8) |
| Both sides | 4 (0.6) | 3 (0.4) | 3 (0.3) | 10 (0.4) |